Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
NCT03841136 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2019-03-28
Summary
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen
Conditions
- Extensive-stage Small Cell Lung Cancer
Interventions
- DRUG
-
anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-01
- Primary Completion
- 2019-12-01
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
NCT04313660 ·Status: UNKNOWN ·Phase: PHASE2
-
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
NCT04314297 ·Status: UNKNOWN ·Phase: PHASE2
-
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06931145 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
NCT04363255 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
NCT03781869 ·Status: UNKNOWN ·Phase: PHASE2
-
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
NCT04731909 ·Status: UNKNOWN ·Phase: NA
-
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
NCT06441344 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
NCT00035516 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
NCT03566576 ·Status: UNKNOWN ·Phase: NA
-
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
NCT03613597 ·Status: UNKNOWN ·Phase: PHASE2
-
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
NCT04985851 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
NCT01357395 ·Status: COMPLETED ·Phase: PHASE2
-
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
NCT04322617 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
NCT04164745 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112346 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
NCT02179528 ·Status: UNKNOWN ·Phase: PHASE2
-
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
NCT04254471 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
NCT04211896 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
NCT06951841 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of Combination Therapy in NSCLC
NCT04544644 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
NCT04234607 ·Status: UNKNOWN ·Phase: PHASE3
-
Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial
NCT06825208 ·Status: NOT_YET_RECRUITING
-
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04005716 ·Status: COMPLETED ·Phase: PHASE3
-
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
NCT05001971 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
NCT04181372 ·Status: UNKNOWN ·Phase: PHASE2